Results 171 to 180 of about 9,892 (240)

Urinary Exosomal Aquaporin-2 Expression and the Efficacy of Tolvaptan in Advanced CKD Patients with Congestive Heart Failure: An Interim Report [PDF]

, 2018
Kenzo Kodaka, Emiko Kuribayashi Okuma, Shigeyuki Arai, Michito Nagura, Yoshifuru Tamura, Shigeru Shibata, Yoshihide Fujigaki, Shunya Uchida   +7 more
openalex   +1 more source

End Point Selection in ADPKD Clinical Trials. [PDF]

Kidney Int Rep
St Pierre K, El-Damanawi R, Jefferis J, Johnson DW, Hawley CM, Staatz CE, Viecelli AK, Mallett AJ.   +7 more
europepmc   +1 more source

4CPS-032 Study of the characteristics of patients treated with tolvaptan

, 2018
MA González González, N Ferreras, Isabel Álvarez, Miguel Guerra, JJ Ortiz de Urbina, GM Flores   +5 more
openalex   +2 more sources

Clinical Variability of ADPKD in Monozygotic Twins. [PDF]

Kidney Int Rep
Mohib O, Van Cauwelaert S, Pölsler L, Van Der Niepen P, Brussaard C, Van Vlem B, Schauer R, Harris PC, Janssens P.   +8 more
europepmc   +1 more source

Tolvaptan use in a patient with TSC2 - PKD1 contiguous gene deletion syndrome – a case report [PDF]

Osasuyi Iyasere, Yusuf Jinadu, Emily Craft   +2 more
openalex   +1 more source

Outcomes of Patients With Autosomal Dominant Polycystic Kidney Disease Prescribed SGLT2 Inhibitors in British Columbia: A Single-Arm Retrospective Cohort Study. [PDF]

Can J Kidney Health Dis
Cau A, Elliott M, Levin A, Karunarathna C, Romann A, Djurdjev O, Atiquzzaman M, Bevilacqua M.   +7 more
europepmc   +1 more source

Efficacy of peritoneovenous shunt for treating tolvaptan-resistant refractory ascites in a cirrhotic patient with portal vein thrombosis: A case report

, 2016
Kota Shigeto, Takumi Kawaguchi, Takashi Niizeki, YASUSHI KUNITAKE, Hidetoshi Takedatsu, Tatsuyuki Tonan, Kiminori Fujimoto, Masatoshi Tanaka, Toshi Abe, Hisanori Naito, Takuji Torimura   +10 more
openalex   +2 more sources

Reduction of polycystic kidney and liver volumes in a patient with tolvaptan-resistant autosomal dominant polycystic kidney disease and acromegaly during lanreotide therapy. [PDF]

CEN Case Rep
Takenaka S, Hattanda F, Kawamura T, Watanabe-Kusunoki K, Nakazawa D, Kameda H, Amengual O, Atsumi T, Nishio S.   +8 more
europepmc   +1 more source

Author Correction: A small molecule stabilizer rescues the surface expression of nearly all missense variants in a GPCR. [PDF]

Nat Struct Mol Biol
Mighell TL, Lehner B.
europepmc   +1 more source

Tolvaptan and its potential in the treatment of hyponatremia

, 2008
Y Howard Lien, Megan B Dixon
openalex   +1 more source